Literature DB >> 17872880

Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events.

Alan H Lipson1, Wendy M Fallis, Xiqui Wang, Yanqing Yi.   

Abstract

OBJECTIVE: To identify patients admitted to hospital with coronary events and to estimate their pre-admission coronary risk, including their lipid levels. Despite the available data and numerous guidelines, evidence indicates that many patients with hyperlipidemia are undertreated and are not achieving target lipid levels.
DESIGN: Retrospective chart review.
SETTING: Acute care community hospital in Winnipeg, Man. PARTICIPANTS: A total of 153 patients who were diagnosed with acute myocardial infarction, unstable angina, or acute coronary syndrome upon admission.
METHOD: Each patient's 10-year risk of developing coronary artery disease was calculated, and his or her risk status was established. Each patient's low-density lipoprotein cholesterol (LDL-C) levels were recorded and categorized based on current Canadian guidelines.
RESULTS: Mean age of patients was 67.6 years; 60.8% were male. Patients in the low-risk category had a mean LDL-C level of 2.98 mmol/L (95% confidence interval [CI] 2.66 to 3.29), and patients in the moderate-risk category had a mean LDL-C level of 3.01 mmol/L (95% CI 2.74 to 3.28), both significantly lower (P < .05) than the LDL-C target levels for patients in those risk categories according to Canadian guidelines. The mean LDL-C level for patients in the very high-risk category, however, was 2.53 mmol/L (95% CI 2.35 to 2.71), above the recommended goal. Almost half the patients (48.3%) in the very high-risk category had LDL-C levels that exceeded the goal. Slightly more than 1 in 3 patients in the very high-risk category was reported to be taking lipid-lowering agents.
CONCLUSION: Patients in the community who are at very high risk of having cardiovascular events are undertreated with respect to attaining LDL-C target levels. These findings point to an opportunity to prevent patient morbidity and reduce the number of hospitalizations for cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872880      PMCID: PMC2234631     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

1.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

Authors:  K K Teo; J R Burton; C E Buller; S Plante; D Catellier; W Tymchak; V Dzavik; D Taylor; S Yokoyama; T J Montague
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

3.  Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey.

Authors:  A I Qureshi; M F Suri; L R Guterman; L N Hopkins
Journal:  Arch Intern Med       Date:  2001-07-09

4.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Authors:  Jacques Genest; Jiri Frohlich; George Fodor; Ruth McPherson
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

5.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.

Authors:  S R Majumdar; J H Gurwitz; S B Soumerai
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

6.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

7.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

8.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

9.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

10.  Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus.

Authors:  A P Lambert; M A Hunt; A P Day; G R Bayly; C M Dayan
Journal:  Diabet Med       Date:  2002-06       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.